Contemporary approaches in aerosolized drug delivery to the lung

Gupta, Pramod; Hickey, Anthony

doi:10.1016/0168-3659(91)90053-g

Cited by 59 publications

(16 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microspheres in the size range 1-5 mm have been delivered as aerosols to the lungs (36), and particles can reside at the site of deposition for extended periods of time prior to uptake by APCs (37). The targets of microsphere delivery are macrophages, which are mobile and number almost a billion in the periphery of the lungs (38).…”

Section: Introductionmentioning

confidence: 99%

Poly (Lactide-co-Glycolide) Microspheres in Respirable Sizes Enhance an In Vitro T Cell Response to Recombinant Mycobacterium tuberculosis Antigen 85B

García-Contreras

et al. 2007

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Poly (Lactide-co-Glycolide) Microspheres in Respirable Sizes Enhance an In Vitro T Cell Response to Recombinant Mycobacterium tuberculosis Antigen 85B

García-Contreras

et al. 2007

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…When actuated, the active ingredient-propellant plume is emitted from the mouthpiece at such a rapid velocity (approximately 100 km/h) that at least 80% of the dose collides with the back of the throat and deposits on the larynx and pharynx regions. There is 10% deposited in the actuator, leaving only approximately 10% to reach the lung for desired therapeutic action (4,(5)(6)(7)14). This phenomenon can lead to several undesirable outcomes.…”

Section: Introductionmentioning

confidence: 99%

Investigation of Some Commercially Available Spacer Devices for the Delivery of Glucocorticoid Steroids from a pMDI

Williams¹,

Patel²,

Barron

et al. 2001

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

Five commercially available spacers were investigated to determine their influence on the percentage of drug retained in the spacer device, percentage fine particle fraction (FPF), percentage deposited in the induction port, mass median aerodynamic diameter (MMAD), and geometric standard deviation (GSD). Betamethasone valerate (BMV) and triamcinolone acetonide (TAA) were used as model drugs in the pressurized metered dose inhaler (pMDI) formulations containing the propellant HFA 134a. The BMV was dissolved in an ethanol/HFA 134a system, and the TAA was suspended in HFA 134a using ethanol as a dispersing agent. The metering chamber volume of the valve was either 50 microl or 150 microl. The spacer devices investigated included the ACE, Aerochamber, Azmacort, Easivent, and Ellipse spacers. Each spacer device was attached to an Andersen Cascade Impactor powered by a vacuum pump. Cascade impaction data were used to derive the percentage drug deposited in the induction port, MMAD, GSD, and FPF. The BMV particles emitted from the spacers were finer than the TAA particles because the dissolved drug precipitated as the cosolvent evaporated. The TAA particles had significantly larger MMADs because many undissolved drug particles were contained within each droplet following actuation. After evaporation of the liquid continuous phase, the suspended drug aggregated to form larger agglomerates than those particles precipitated from the BMV pMDI solution droplets. The addition of a spacer device lowered the MMAD to less than 4.7 microm for particles from both the BMV pMDI solution and the TAA pMDI suspension. The addition of a spacer device also lowered the percentage drug deposited in the induction port. The FPF was significantly increased when a spacer device was used. The MMAD significantly decreased when a spacer device was added for the two model drugs when using the 150-microl metering valves, but the difference was not statistically significant when the 50-microl valves were used (P < .05). The GSD was not influenced by the use of a spacer device. The use of a spacer device will enhance pMDI therapy by reducing the amount of drug deposited in the oropharyngeal region, which will lead to fewer instances of local and systemic side effects. In addition, the spacer devices investigated will allow a higher dose of drug to reach the deep lung, which may permit the use of lower dosage regimens with increased therapeutic efficacy.

show abstract

“…It has been shown that lung immunization of guinea pigs with BCG nanomicroparticles significantly reduced bacterial burden and lung pathology compared to animals immunized with standard parenteral BCG (11). However, lung delivery requires the particle size to have an aerodynamic diameter of 1-5µm (12).…”

Section: Introductionmentioning

confidence: 98%

PLGA Microparticles in Respirable Sizes Enhance an In Vitro T Cell Response to Recombinant Mycobacterium Tuberculosis Antigen TB10.4-Ag85B

Shi

Hickey

2009

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

Contemporary approaches in aerosolized drug delivery to the lung

Cited by 59 publications

References 95 publications

Poly (Lactide-co-Glycolide) Microspheres in Respirable Sizes Enhance an In Vitro T Cell Response to Recombinant Mycobacterium tuberculosis Antigen 85B

Poly (Lactide-co-Glycolide) Microspheres in Respirable Sizes Enhance an In Vitro T Cell Response to Recombinant Mycobacterium tuberculosis Antigen 85B

Investigation of Some Commercially Available Spacer Devices for the Delivery of Glucocorticoid Steroids from a pMDI

PLGA Microparticles in Respirable Sizes Enhance an In Vitro T Cell Response to Recombinant Mycobacterium Tuberculosis Antigen TB10.4-Ag85B

Contact Info

Product

Resources

About